

CORRECTION

Open Access



Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Wan-Ling Tan¹, Quan Sing Ng¹, Cindy Lim², Eng Huat Tan¹, Chee Keong Toh¹, Mei-Kim Ang¹, Ravindran Kanesvaran¹, Amit Jain¹, Daniel S. W. Tan^{1,3} and Darren Wan-Teck Lim^{1,4*}

Correction to: *BMC Cancer* (2018) 18:1198
DOI: 10.1186/s12885-018-5110-2

Following publication of the original article [1], the authors notified us of a typographical error in Table 1.

The corrected Table 1 is presented below.

Author details

¹Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. ²Clinical Trials & Epidemiological Sciences, National Cancer Centre Singapore, Singapore, Singapore. ³Genome Institute of Singapore, A*STAR, Singapore, Singapore. ⁴Institute of Molecular and Cell Biology, A*STAR, Singapore, Singapore.

Received: 14 December 2018 Accepted: 14 December 2018

Published online: 24 December 2018

Reference

1. Tan, et al. Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases. 2018, 2018;18:1198. <https://doi.org/10.1186/s12885-018-5110-2>.

* Correspondence: darren.lim.w.t@singhealth.com.sg

¹Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore

⁴Institute of Molecular and Cell Biology, A*STAR, Singapore, Singapore



Table 1 Patient Baseline Characteristics. The baseline demographics and clinical characteristics of patients with advanced EGFRm + NSCLC treated with first-line afatinib ($n = 125$) in our cohort

Characteristic	No.	%
Sex		
Male	64	51.2
Female	61	48.8
Age at diagnosis, years		
Median	62	
Range	26–86	
Ethnicity		
Chinese	100	80.0
Malay	14	11.2
Indian	3	2.4
Others	8	6.4
Smoking status		
Never	95	76.0
Former	17	13.6
Current	13	10.4
Histotype – NSCLC		
Adenocarcinoma	121	96.8
Adenosquamous carcinoma	1	0.8
NOS	3	2.4
EGFR mutation type		
Exon 19 deletion ^[a]	87	69.6
Exon 21 L858R	27	21.6
Others ^[b]	11	8.8
Brain metastases at baseline		
No	82	65.6
Yes	42	33.6
Unknown	1	0.8
Starting dose of afatinib once daily (OD)		
40 mg	62	49.6
30 mg	61	48.8
20 mg	1	0.8
Unknown	1	0.8

^aE746_A750del; E746_A750delinsIP; E746_A750delinsQP; E746_A750delinsVP; E746_T751delinsV; E746_S752delinsV; E746_P753delinsVS; L747_A750delinsP; L747_T751del; L747_P753delinsS; NOS

^bE697Q; A763_Y764insFQEA; Double mutation; Unknown NSCLC Non-small cell lung cancer, NOS Not otherwise specified